Presidio Medical

Founded as a clinical-stage, privately held medtech company, Presidio Medical is dedicated to developing a transformational neuromodulation platform aimed at treating diseases caused by undesired neural activity. Their core mission is to provide innovative remedies for disorders affecting neuronal activity, thereby improving patient outcomes and quality of life. The company's primary product leverages ultra-low frequency current waveforms to reversibly block axonal conduction and manage chronic pain, positioning them at the forefront of neuromodulation therapies.

Notable affiliated individuals include Martyn G. Jones, Evan Rogers, and James P. Harris, who have contributed to significant scientific publications in the field. Presidio Medical has achieved key milestones in clinical trials, demonstrating the efficacy of their neuromodulation platform in managing chronic pain. Their impact is marked by advancing the treatment landscape for neural disorders, offering new hope for patients with conditions previously deemed difficult to manage.